"We are prepared to push the boundaries to accelerate drug discovery," Jan Lundberg, executive vice president of science and technology and president of Lilly Research Laboratories, said. "Our expanded capabilities at the New York site will further Lilly's expertise in our core therapeutic areas and help pave the way for broader collaboration with leading academic, healthcare and industry colleagues."
The facilities will be completed in 2016. The space will include a translational immuno-oncology hub and a Lilly "portal," which will allow local academic scientists to access innovative drug discovery capabilities.
"Going forward, immuno-oncology research will focus on new ways to harness the immune system and on combination therapies with targeted agents," Lundberg said. "Cancer is a complex disease. Our diverse research approach and expansion in New York will ultimately put us in a strong position to advance the delivery of innovative medicines to patients."
This is Lilly's third research and development expansion this year; Lilly also announced it would build a delivery and device innovation center in Cambridge and expand its biotechnology center in San Diego, California.
Eli Lilly and Company is committed to supporting projects that promote excellence in patient care and provide valuable information to the medical and patient advocacy communities.